1. Academic Validation
  2. Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria

Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria

  • Nat Commun. 2024 Dec 4;15(1):10557. doi: 10.1038/s41467-024-54969-6.
Junjie Zhu 1 Fu-Ying Qin 1 Saifei Lei 1 Ruizhi Gu 1 Qian Qi 1 Jie Lu 1 Karl E Anderson 2 Peter Wipf 3 Xiaochao Ma 4
Affiliations

Affiliations

  • 1 Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
  • 2 Porphyria Laboratory & Center, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
  • 3 Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA.
  • 4 Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. mxiaocha@pitt.edu.
Abstract

Erythropoietic protoporphyria (EPP) is a genetic disease characterized by protoporphyrin IX-mediated painful phototoxicity. Currently, options for the management of EPP-associated phototoxicity are limited and no oral medication is available. Here, we investigated a novel therapy against EPP-associated phototoxicity by targeting the ATP-binding cassette subfamily G member 2 (ABCG2), the efflux transporter of protoporphyrin IX. Oral ABCG2 inhibitors were developed, and they successfully prevented EPP-associated phototoxicity in a genetically engineered EPP mouse model. Mechanistically, ABCG2 inhibitors suppress protoporphyrin IX release from erythroid cells and reduce the systemic exposure to protoporphyrin IX in EPP. In summary, our work establishes a novel strategy for EPP therapy by targeting ABCG2 and provides oral ABCG2 inhibitors that can effectively prevent protoporphyrin IX-mediated phototoxicity in mice.

Figures
Products